Peregrine shares surge on regulatory pact for late-stage cancer drug; AZ hunts for spot for new R&D complex;

 @FierceBiotech:  Life sciences VC firm launches 'crowdfunding' site for limited crowd. More | Follow @FierceBiotech

 @JohnCFierce: Pentagon advisor pocketed biotech's cash while promoting its interests - via LATimes. Report | Follow @JohnCFierce

 @RyanMFierce: Interesting 'Open Research Exchange' platform debuts for creating outcome measures from the crowd. Release | Follow @RyanMFierce

> Shares of Peregrine Pharmaceuticals ($PPHM) shot up 19% early today after the biotech reported that it had reached an agreement with the FDA on the design of a late-stage study of the cancer drug bavituximab. The primary focus is on overall survival compared to chemotherapy. Story

> AstraZeneca ($AZN) officials are reportedly looking closely at a biomedical park near Cambridge in the U.K. as a likely site for its planned $500 million R&D complex, a central feature in its restructuring. Story

> Over the weekend Lundbeck touted Phase III data for the depression drug Brintellix (vortioxetine) demonstrating improvements in patients' symptoms. Report

> The Boston Globe reports on the nanotech work being done by biotech entrepreneur Omid Farokhzad, a close associate of MIT's Robert Langer. Story

Medical Device News

 @FierceMedDev:  Shoe-mounted lever could power artificial heart pumps. More | Follow @FierceMedDev

 @MarkHFierce: Check out FierceDrugDelivery's latest - a great look at some advances in nanotech drug delivery. Special report | Follow @MarkHFierce

 @DamianFierce:  PRA is lining up to go public, filing a confidential draft with the SEC. Article | Follow @DamianFierce

> FDA slaps deadly label on Abbott's glucose meter recall. News

> PIP attorneys plead for leniency in breast implant fraud trial. Report

> Medtronic wins CE mark for clot-removal tech. More

Pharma News

 @FiercePharma: Biopharma's 20 highest-paid CEOs. Our latest special report on exec pay. Report | Follow @FiercePharma

 @EricPFierce: AstraZeneca rides Crestor to top of cardio drug list. Special report | Follow @EricPFierce

> Women want Apotex to pay for unwanted pregnancies. Article

> Actavis nabs Warner Chilcott in a $8.5B stock swap. News

> JVs like Pfizer, Hisun hookup provide Chinese companies shot at Western markets. Report

CRO News

> Nordion inks CMO deal with Navidea. Report

> After successful IPO, Quintiles plots 400 job cuts. Item

> PRA winds up for IPO. News

> Quintiles signs on to help Merck KGaA right the R&D ship. More

> PPD's BioDuro opens Shanghai discovery lab. Story

>WuXi's revenue jumps 11.7% in strong Q1. Article

Biotech IT News

> Drugmaker UCB taps IBM for digital medicine effort. Article

> InSilico Genomics grabs $1.5M for fledgling bioinformatics biz. Report

> Life sciences VC firm launches 'crowdfunding' site for limited crowd. Article

> Sanofi hunts for clinical trial recruits in growing social network. Story

> Merck targets docs with revamped U.K. website and healthcare apps. News

And Finally… Should we be wary of genomics' potential to treat cancer better? Blog

Suggested Articles

The deal, which features an additional $2 billion in milestones, will give Bayer control of an AAV platform and a clinical-phase pipeline.

The result, which beats the 35% reported by KRAS rival Amgen, sets Mirati up to file for FDA approval of the drug in the second half of next year.

Scorpion is working on precision oncology 2.0, including making better drugs for known targets, hitting undruggable targets and discovering new ones.